1. Home
  2. Insights
  3. Blog
  4. Navigating the EU Packaging & Packaging Waste Regulation (PPWR): Implications for pharmaceutical labelling and beyond

Navigating the EU Packaging & Packaging Waste Regulation (PPWR)

Implications for pharmaceutical labelling and beyond

The European Union’s Packaging & Packaging Waste Regulation (PPWR) represents one of the most significant regulatory shifts in decades for companies placing products on the EU market. With applicability from 12 August 2026, this regulation introduces far-reaching changes to packaging design, labelling and lifecycle management, with particular implications for the pharmaceutical sector.

In this article, we explore the background to PPWR, its key provisions, the operational impact on life sciences companies and ICON’s recommendations to support early and effective compliance.

Background: Why PPWR is happening

The PPWR (Regulation (EU) 2025/40) was introduced as part of the EU’s broader Green Deal and Circular Economy Action Plan, reflecting the growing urgency to address packaging waste and resource inefficiency.

Packaging is a major environmental concern: it accounts for a significant share of raw material consumption and municipal waste in the EU, with volumes continuing to rise. At the same time, fragmented national regulations have created complexity and barriers within the single market, increasing costs and compliance risks for industry. 

The PPWR therefore aims to:

  • Reduce packaging waste and environmental impact
  • Promote recyclability, reuse and circularity
  • Harmonise requirements across all EU Member States
  • Improve transparency through standardised labelling 

Unlike the previous, Packaging and Packaging Waste Directive (94/62/EC), the PPWR is a directly applicable regulation, ensuring a single, consistent framework across Europe.

Key highlights: What the regulation covers

The PPWR is a comprehensive framework spanning the entire packaging lifecycle, from design and manufacture through to disposal and recycling.

ICON’s internal assessment highlights three core pillars:

1. Sustainable packaging requirements

Packaging must meet strict sustainability criteria, including:

  • Minimisation of substances of concern (e.g. PFAS)
  • Mandatory recyclability standards
  • Minimum recycled content targets for plastics from 2030 onwards
  • Reduction of weight and volume to the minimum necessary by 2030

2. Labelling, marking and information requirements

A major operational shift will be the introduction of harmonised EU-wide labelling:

  • From 12 August 2028 (or 24 months after implementing acts), all packaging must carry a harmonised label showing material composition to support consumer sorting
  • Label must use pictograms, be easy to understand and also accessible for people with disabilities
  • Optional QR codes may provide additional sorting instructions for each component
  • Packaging containing substances of concern requires digital marking 

For reusable packaging:

  • From 12 February 2029 (or 30 months after implementing acts) 
    • “Reusable” labelling is required
    • QR codes must provide reuse system details

3. Technical and digital requirements

The regulation introduces new expectations around:

  • Standardised claims for recycled or biobased content
  • Strict rules on label placement, visibility and legibility
  • Prohibition of misleading sustainability claims

Impact: What this means for pharma and life sciences

The PPWR applies broadly to all packaging placed on the EU market, regardless of material or origin and across all economic operators — including manufacturers, importers and distributors.

For pharmaceutical companies, the implications are particularly complex.

Operational and regulatory impact

ICON’s analysis identifies several key challenges:

  • Packaging redesign across cartons, blisters, bottles and leaflets
  • Increased regulatory burden, including potential variations and stability studies
  • Artwork complexity, due to additional pictograms and sustainability information
  • Supplier and material challenges, including requalification and audits
  • Data governance requirements for packaging composition and compliance
  • Risk of supply disruption if transitions are not aligned

Pharmaceutical packaging must also continue to meet strict requirements for patient safety, stability and sterility, which can limit redesign flexibility and create tension with sustainability targets.

Key milestones and timelines

RequirementImplementation deadline
PPWR becomes applicable12 August 2026
Harmonised packaging labelling (including pictograms) 12 August 2028
Reusable packaging labelling 12 February 2029
Methodology for substances of concern2030 onwards

The phased approach means that labelling changes in 2028 and 2029 will likely drive early transformation programmes, particularly given long pharmaceutical change timelines.

ICON’s recommendations for sponsors and clients

At ICON, we view PPWR not as a standalone regulatory change, but as a strategic transformation across the product lifecycle.

1. Start early with impact assessments

Companies should:

  • Conduct portfolio-wide packaging audits
  • Identify high-risk SKUs and constrained formats
  • Map labelling and data gaps against PPWR requirements

Early assessment is critical given long regulatory and supply chain lead times.

2. Align packaging changes with regulatory strategy

  • Integrate PPWR changes into existing variation and lifecycle management plans
  • Synchronise updates with regulatory submission cycles

3. Strengthen cross-functional governance

PPWR cuts across multiple functions. Successful implementation requires:

  • Alignment between Regulatory Affairs, Labelling, Quality, Packaging Engineering and Sustainability
  • Centralised decision-making and data governance frameworks

4. Engage suppliers proactively

  • Assess supplier readiness and material availability
  • Initiate requalification activities early
  • Mitigate risk of non-compliant or unavailable materials

5. Prepare for digital and data requirements

  • Establish robust packaging data management systems
  • Plan for QR code integration and digital labelling content
  • Ensure compliance with pre-purchase information requirements

Conclusion

The PPWR marks a fundamental shift in packaging regulation across the EU, with far-reaching implications for pharmaceutical labelling, supply chains and regulatory strategy.

While timelines extend to 2028, 2029 and beyond, the complexity of implementation  particularly for regulated products means action must begin now.

ICON supports clients across the full lifecycle of regulatory labelling and packaging transformation, from early impact assessment through to implementation and market compliance, helping organisations navigate PPWR with confidence and maintain continuity of supply in an evolving regulatory landscape. If you would like to know more about how to navigate the impact of PPWR, please contact our team at RCSLabeling@iconplc.com.

 

References

In this section

Connect with us